Product Description: Givinostat (ITF-2357) is a HDAC inhibitor with an IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat can be used for Duchenne muscular dystrophy (DMD) research[1].
Applications: Cancer-programmed cell death
Formula: C24H27N3O4
Citations: Acta Pharmacol Sin. 2021 Apr 13./Cell Prolif. 2021 May 24;e13072./Commun Biol. 2021 Oct 29;4(1):1235./J Am Chem Soc. 2024 Sep 27./J Orthop Transl. 29 (2021) 106-112./Neuroscience. 2021 Apr 13;S0306-4522(21)00185-8./Patent. US20240252638A1./SSRN. 2024 Mar 13./Cell Death Dis. 2020 Sep 15;11(9):753./J Mol Med (Berl). 2019 Aug;97(8):1183-1193.
References: [1]Li S, et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem. 2015 Jan 23;290(4):2368-78./[2]Wang YG, et al. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol. 2015 Jul 21;21(27):8326-39./[3]Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005 Jan-Dec;11(1-12):1-15.
CAS Number: 497833-27-9
Molecular Weight: 421.49
Compound Purity: 98.16
Research Area: Cancer; Inflammation/Immunology
Solubility: DMSO : 250 mg/mL (ultrasonic)
Target: HDAC
English
Deutsch
